arrow
Return

Reevaluating Corticosteroid Classification Models in Patient Patch Testing

delete2022-11-01
delete7
delete
OA
AI
J
Joyce Y. Chen
J
James A. Yiannias
M
Matthew R. Hall
M
Molly J. Youssef
L
Lisa A. Drage
M
Mark D.P. Davis
Y
Yul W. Yang *
DOI:10.1001/jamadermatol.2022.3774delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
IMPORTANCE Individuals with allergic contact dermatitis to one topical corticosteroid may also react to other corticosteroids. Corticosteroid classification models have been proposed to predict such copositivity, recommend representative screening corticosteroids, and guide allergen avoidance. OBJECTIVE To use patient data to determine copositivity patterns between corticosteroids and evaluate against previous corticosteroid classification models. DESIGN, SETTING, AND PARTICIPANTS This qualitative study included a retrospective analysis of the Mayo Clinic Contact Dermatitis Group corticosteroid patch test data from 2010 to 2019. Among patients undergoing patch testing with the Mayo Clinic's standard or steroid series who consented to research participation, 5637 patients were included in the analysis. Copositivity rates were determined between corticosteroids and analyzed by hierarchical clustering for comparison to previous classification models. MAIN OUTCOMES AND MEASURES The frequency of patch test positivity to each of the analyzed corticosteroids was noted and compared with previously published patch test positivity rates. Copositivity rates between each pair of corticosteroids were determined, and overall copositivity patterns were analyzed and evaluated against known steroid classes. RESULTS A total of 49 472 individual patches were applied to 5637 patients, testing 18 corticosteroids. Patch test positivity rates ranged between 0.3% and 4.7%. The fluocinonide positivity rate corresponded to the highest copositivity rate with other corticosteroids (mean [SD], 50.7%[26.1%]). Tixocortol-21-pivalate, 0.1%, and tixocortol-21-pivalate, 1%, positivity rates corresponded to the lowest copositivity rates (mean [SD], 4.1% [1.7%] and 3.6%[1.4%], respectively). Hierarchical clustering elucidated patterns that did not support previous corticosteroid classification models. CONCLUSIONS AND RELEVANCE In this qualitative study, copositivity rates were variable between corticosteroids, and overall patch test positivity for allergy to topical corticosteroids was rare. Previously published corticosteroid classifications are not supported by real patient-derived data and may not be accurate in predicting corticosteroid copositivity.
Keywords:
CONTACT-DERMATITIS
CROSS-REACTIVITY
TIXOCORTOL PIVALATE
ALLERGY
HYPERSENSITIVITY
SERIES

Journal

J
JAMA Dermatology
IF:
11
Papers:
4.3K
Citations:
1.1W

Organization

M
mayo clinic
Scholars:
8.3W
Papers: 6.6W
Citations: 85
M
mayo clinic phoenix
Scholars:
7.0K
Papers: 5.6K
Citations: 4
Cited Papers

Cited Papers

Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
err2008-03-12
err0
PREAI
errPAUL MATHEW; GREGORY J. AHMANN; THOMAS E. WITZIG; PATRICK C. ROCHE; ROBERT A. KYLE; PHILIP R. GREIPP
errShare
errSave
Patch Test Reactions to Corticosteroids: Retrospective Analysis From the North American Contact Dermatitis Group 2007-2014
err2017-01-01
err24
PREAI
errPratt, Melanie D.; Mufti, Asfandyar; Lipson, Jennifer; Warshaw, Erin M.; Maibach, Howard I.; Taylor, James S.; Sasseville, Denis; DeKoven, Joel G.; Zirwas, Matthew J.; Fransway, Anthony F.; Mathias, C. G. Toby; Zug, Kathryn A.; DeLeo, Vincent A.; Fowler, Joseph F., Jr.; Marks, James G.; Storrs, Frances J.; Belsito, Donald V.
errShare
errSave
Cytogenetic, Genomic, and Functional Characterization of Pituitary Gonadotrope Cell Lines
err2019-03-25
err0
errOAAI
errFrederique Ruf-Zamojski; Yongchao Ge; Hanna Pincas; Jidong Shan; Yinghui Song; Nika Hines; Kevin Kelley; Cristina Montagna; Pranav Nair; Chirine Toufaily; Daniel J Bernard; Pamela L Mellon; Venugopalan Nair; Judith L Turgeon; Stuart C Sealfon
errShare
errSave
errShare
errSave
Contact allergy to corticosteroids
err2001-12-24
err127
errOAAI
errMatura, M; Goossens, A; Matura, M
errShare
errSave
Contact Allergy Cross-reactions and Thresholds: A Review
err2021-12-02
err5
PREAI
errScheman, Andrew; Ruggiero, Jenna L.; Kerchinsky, Lillian; Zippin, Jonathan H.; Zirwas, Matthew; Lugo-Somilinos, Aida; Hylwa, Sara
errShare
errSave
Contact hypersensitivity to tixocortol pivalate
err1998-05-01
err22
PREAI
errLutz, ME; el-Azhary, RA; Gibson, LE; Fransway, AF
errShare
errSave
Defining Topical Corticosteroids by Allergenicity and Cross-Reactivity for the Contact Allergen Management Program
err2020-03-23
err2
PREAI
errGupta, Rachit; Hylwa, Sara; Zirwas, Matthew; Lugo-Somolinos, Aida; Zippin, Jonathan H.; Scheman, Andrew
errShare
errSave
researcher View more